Can-Fite BioPharma Ltd.

Regulatory Filings • May 2, 2023

_________ false

��-���� ������� ��"�	2 381
CAN-FITE BIOPHARMA LTD
Corporation no: 512022153	4330
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C003 ( Public )		Reported via MAGNA:	02/05/2023
	www.isa.gov.il			www.tase.co.il				Reference:	2023-02-046995	Time of broadcast: 12:13 12:13

---

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

ea177843-6k_canfitebioEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2023-02-009460
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 21/02/2023
Address: Bareket 10 , Petach-Tikva 47190   , Tel: 03-9241114 , 03-9213501 Fax: 03-9249378
E-mail address: motti@canfite.co.il   Company site: www.canfite.com
Previous names of reporting entity:
Name of the Signatory: FISHMAN PNINA Position of Signatory in the reporting corporation: Director, CFO Name of Employer Company:
Address: BAR-ON 2 , HERZLIA 4658084 Telephone: 03-9241114 Facsimile: 03-9249378 E-mail: pnina@canfite.co.il 2